金龙胶囊配合肝动脉化疗栓塞术治疗原发性肝癌的疗效及机制分析

Clinical Efficacy and Mechanism of Jinlong Capsule Plus Hepatic Artery Embolism for Primary Liver Cancer

目的观察金龙胶囊配合肝动脉化疗栓塞（TACE）术治疗原发性肝癌的疗效及机制分析。方法将116例原发性肝癌患者，按数字表法随机分为对照组和治疗组，每组各58例；对照组采取单纯肝动脉化疗栓塞术（每4—10周重复治疗，最多治疗次数为12次）治疗，治疗后进行常规保肝治疗；治疗组在对照组基础上给予金龙胶囊（4粒／次，3次／d）内服治疗，连续服用3年；检测两组治疗后1周和1个月患者血清癌胚抗原（CEA）和甲胎蛋白（AFP）水平；比较两组临床疗效；检测两组外周血T淋巴细胞亚群变化。结果两组患者治疗后1周血清CEA和AFP水平均略低于术前；治疗后1个月，治疗组患者血清CEA和AFP水平均明显低于对照组，（P〈0．01）；治疗组近期总缓解率为67．24％，对照组为41．38％，治疗组优于对照组（χ^2=6．809，P〈0．01）；治疗后3个月，治疗组CD3^＋和CD4^＋值均明显高于对照组，而CD8^＋值明显低于对照组，比较差异均有统计学意义（P〈0．01）。结论金龙胶囊联合TACE治疗原发性肝癌能明显降低患者血清CEA和AFP水平，提高患者免疫功能，其临床疗效优于单纯TACE治疗。

Objective To study the clinical efficacy and mechanism of Jinlong capsule plus hepatic artery embolism chemotherapy for primary liver cancer. Methods 116 patients with primary liver cancer were randomly divided into the control group and the treatment group according to the random number table method, and each with 58 cases. The control group received single hepatic artery embolism chemotherapy（ repeat treatment every 4 - 10 week and at best 12 times）, and conventional liver protecting treatment. Based on the control group, the treatment group were orally given Jinlong capsule（4pellets/time and tid） for 3 years. Serum levels of CEA and AFP were detected between the 2 groups 1 week and 1 month after treatment. Clinical efficacy was compared between the 2 groups. Level of T lymphocyte subpopulation in peripheral blood was measured in the 2 groups. Restilts Serum levels of CEA and AFP in both groups after treatment were slightly higher than that before treatment. Serum levels of CEA and AFP in the treatment group were obviously lower than those of the control group 1 month after treatment（ P 〈 0.01 ）. The total remission rate of the treatment group was 67.24%, which was superior to the control group,41.38% （χ^2 = 6. 809, P 〈 0.01 ）. CD3^＋ and CD4^＋ in peripheral blood of the treatment group were higher than that of the control group,while CD8^＋ was lower than that of the control group, there had statistic difference （ P 〈 0.01 ）. Conclusion Jinlong capsule combined with hepatic artery embolism for primary liver cancer could decrease serum levels of CEA and AFP, improve patients＇ cellular immune function, and its clinical efficacy is superior to single hepatic artery embolism chemotherapy.